SAB Biotherapeutics
SABS
SABS
34 hedge funds and large institutions have $2.41M invested in SAB Biotherapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Holders
34
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$319K | |
| 2 | +$35.2K | |
| 3 | +$17.5K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.95K |
| 5 |
Renaissance Technologies
New York
|
+$2.36K |
Top Sellers
| 1 | -$69.7K | |
| 2 | -$43K | |
| 3 | -$30K | |
| 4 |
VF
Virtu Financial
New York
|
-$21K |
| 5 |
Two Sigma Investments
New York
|
-$20.8K |